A 52-week, international, multi-center, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100 mg od [once daily], lumiracoxib 100 mg bid [twice daily] and celecoxib 200 mg od in patients with primary osteoarthritis of hip, knee, hand or spine
Phase of Trial: Phase III
Latest Information Update: 18 May 2012
At a glance
- Drugs Celecoxib; Lumiracoxib
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Novartis
- 18 May 2012 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
- 18 Dec 2005 New trial record.